Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Xenetic Biosciences, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

FRAMINGHAM, MA / ACCESS NEWSWIRE / OCTOBER 10, 2025 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNO-ONCOLOGY TECHNOLOGIES ADDRESSING DIFFICULT TO TREAT CANCERS, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN OFFERING OF 735,000 SHARES OF COMMON STOCK AT A PRICE TO THE PUBLIC OF $6.12 PER SHARE, FOR GROSS PROCEEDS OF APPROXIMATELY $4.5 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER ESTIMATED OFFERING EXPENSES. ALL SHARES OF COMMON STOCK ARE BEING OFFERED BY XENETIC.

XENETIC BIOSCIENCES, INC. ANNOUNCES PRICING OF $4.5 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK

EXPANDED STRATEGIC PARTNERSHIP WITH THE SCRIPPS RESEARCH INSTITUTE TO ADVANCE PROOF-OF-CONCEPT STUDIES AND FURTHER DEVELOP ITS PROGRAM COMBINING SYSTEMIC DNASE I WITH CAR T-CELL THERAPIES ENDED THE QUARTER WITH $4.8 MILLION OF CASH TO FUND OPERATIONS FRAMINGHAM, MA / ACCESS NEWSWIRE / AUGUST 13, 2025 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNO-ONCOLOGY TECHNOLOGIES ADDRESSING DIFFICULT TO TREAT CANCERS, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE SECOND QUARTER 2025. RECENT HIGHLIGHTS EXPANDED ITS COLLABORATION WITH THE SCRIPPS RESEARCH INSTITUTE ("TSRI") TO ADVANCE THE DEVELOPMENT OF THE COMPANY'S DEVELOPMENT PROGRAM EVALUATING THE COMBINATION OF SYSTEMIC DNASE I AND CAR T-CELL THERAPIES; ANNOUNCED ADVANCEMENTS FROM ITS COLLABORATION PARTNER, PERINESS LTD.

XENETIC BIOSCIENCES, INC. REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

INVESTIGATOR INITIATED STUDY WITH COLLABORATION PARTNER, PERINESS, TO BE CONDUCTED AT THE TEL-AVIV SOURASKY MEDICAL CENTER FRAMINGHAM, MA / ACCESS NEWSWIRE / JULY 30, 2025 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNO-ONCOLOGY TECHNOLOGIES ADDRESSING DIFFICULT TO TREAT CANCERS, TODAY ANNOUNCED THAT ITS COLLABORATION PARTNER, PERINESS LTD. ("PERINESS"), HAS ENTERED INTO A CLINICAL STUDY AGREEMENT (THE "AGREEMENT") TO SUPPORT AN EXPLORATORY CLINICAL STUDY OF DNASE I IN COMBINATION WITH ANTI-CD19 CAR T CELLS IN PATIENTS WITH LARGE B CELL LYMPHOMA.

XENETIC BIOSCIENCES, INC. ANNOUNCES ENTRY BY COLLABORATION PARTNER INTO CLINICAL STUDY AGREEMENT TO ADVANCE DEVELOPMENT OF DNASE PLATFORM FOR THE TREATMENT OF LARGE B CELL LYMPHOMA

RESEARCH AND DEVELOPMENT COLLABORATION PROGRAM TO INCLUDE ADDITIONAL MODELS OF LYMPHOMA AND LEUKEMIA TO FURTHER VALIDATE DNASE-I DATA DEMONSTRATED TO DATE FRAMINGHAM, MA / ACCESS NEWSWIRE / JULY 23, 2025 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNO-ONCOLOGY TECHNOLOGIES ADDRESSING HARD TO TREAT ONCOLOGY INDICATIONS, TODAY ANNOUNCED IT HAS CONTINUED ITS COLLABORATION WITH THE SCRIPPS RESEARCH INSTITUTE ("TSRI") TO ADVANCE THE DEVELOPMENT OF THE COMPANY'S DEVELOPMENT PROGRAM EVALUATING THE COMBINATION OF SYSTEMIC DNASE I AND CAR T-CELL THERAPIES. XENETIC'S SYSTEMIC DNASE I CANDIDATE, XBIO-015, IS CURRENTLY IN PRECLINICAL DEVELOPMENT IN COMBINATION WITH CAR-T CELL THERAPY FOR BOTH HEMATOLOGIC AND SOLID TUMORS.

XENETIC BIOSCIENCES, INC. EXPANDS RESEARCH AND DEVELOPMENT COLLABORATION WITH THE SCRIPPS RESEARCH INSTITUTE TO ADVANCE DNASE PLATFORM

INVESTIGATOR INITIATED EXPLORATORY CLINICAL STUDY BEING CONDUCTED IN ISRAEL PURSUANT TO AGREEMENT WITH COLLABORATION PARTNER, PERINESS COMPANY EVALUATING SYSTEMIC RECOMBINANT HUMAN DNASE I (DNASE I) IN COMBINATION WITH CHEMOTHERAPY AND IMMUNOTHERAPY PLATFORMS FOR THE TREATMENT OF PANCREATIC CARCINOMA, COLORECTAL CANCER AND OTHER LOCALLY ADVANCED OR METASTATIC SOLID TUMORS FRAMINGHAM, MA / ACCESS NEWSWIRE / JULY 8, 2025 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNO-ONCOLOGY TECHNOLOGIES ADDRESSING DIFFICULT TO TREAT CANCERS, TODAY ANNOUNCED THAT ITS COLLABORATION PARTNER, PERINESS LTD. (PERINESS), HAS INFORMED THE COMPANY THAT BNEI ZION MEDICAL CENTER HAS COMMENCED PATIENT DOSING IN AN EXPLORATORY CLINICAL STUDY OF SYSTEMIC DNASE I IN COMBINATION WITH FOLFIRINOX FOR THE FIRST LINE TREATMENT OF UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER.

XENETIC BIOSCIENCES, INC. ANNOUNCES UPDATE FROM COLLABORATION PARTNER OF FIRST PATIENT DOSED IN EXPLORATORY CLINICAL STUDY OF DNASE I IN COMBINATION WITH FOLFIRINOX FOR THE FIRST LINE TREATMENT OF UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER

STRATEGIC FOCUS ON EXPLORATORY INVESTIGATOR-INITIATED CLINICAL STUDIES WITH INSTITUTIONAL PARTNERS CONTINUED PROGRESS OF DNASE I DEVELOPMENT PROGRAM TOWARDS IND AND FIRST-IN-HUMAN STUDY FOR TREATMENT OF PANCREATIC CARCINOMA ENDED THE QUARTER WITH $5.2 MILLION OF CASH TO FUND OPERATIONS  FRAMINGHAM, MA / ACCESS NEWSWIRE / MAY 14, 2025 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNO-ONCOLOGY TECHNOLOGIES ADDRESSING DIFFICULT TO TREAT CANCERS, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2025. RECENT HIGHLIGHTS ANNOUNCED THAT ITS COLLABORATION PARTNER, PERINESS LTD.

XENETIC BIOSCIENCES, INC. REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

- DR. REID BISSONNETTE, EXECUTIVE CONSULTANT FOR TRANSLATIONAL RESEARCH AND DEVELOPMENT AT XENETIC, DISCUSSES POSITIVE PRECLINICAL DATA RECENTLY PRESENTED AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) SPRING SCIENTIFIC 2025 CELL THERAPY MEETING - WATCH THE "WHAT THIS MEANS" VIDEO HERE FRAMINGHAM, MA / ACCESS NEWSWIRE / APRIL 9, 2025 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNE-ONCOLOGY TECHNOLOGIES ADDRESSING DIFFICULT TO TREAT CANCERS, TODAY ANNOUNCED THAT DR. REID BISSONNETTE, EXECUTIVE CONSULTANT FOR TRANSLATIONAL RESEARCH AND DEVELOPMENT AT XENETIC PARTICIPATED IN A VIRTUAL INVESTOR "WHAT THIS MEANS" SEGMENT . AS PART OF THE SEGMENT, DR. BISSONNETTE DISCUSSED KEY HIGHLIGHTS FROM THE COMPANY'S RECENT POSTER PRESENTATION TITLED, "DNASE I INTERVENTION ENHANCES CAR-T CELL THERAPY IN SOLID TUMORS BY TARGETING NEUTROPHIL EXTRACELLULAR TRAPS IN METASTATIC MELANOMA," WHICH WAS PRESENTED AT THEAT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) SPRING SCIENTIFIC 2025 CELL THERAPY MEETING.

XENETIC BIOSCIENCES, INC. RELEASES VIRTUAL INVESTOR "WHAT THIS MEANS" SEGMENT

INVESTIGATOR INITIATED STUDY WITH COLLABORATION PARTNER, PERINESS, TO BE CONDUCTED AT THE TEL-AVIV SOURASKY MEDICAL CENTER FRAMINGHAM, MA / ACCESS NEWSWIRE / MARCH 26, 2025 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNO-ONCOLOGY TECHNOLOGIES ADDRESSING DIFFICULT TO TREAT CANCERS, TODAY ANNOUNCED THAT ITS COLLABORATION PARTNER, PERINESS LTD. ("PERINESS"), HAS ENTERED INTO A CLINICAL STUDY AGREEMENT (THE "AGREEMENT") TO SUPPORT AN EXPLORATORY CLINICAL STUDY OF XENETIC'S SYSTEMIC DNASE I CANDIDATE, XBIO-015, IN PATIENTS WITH RELAPSED/REFRACTORY OSTEOSARCOMA AND EWING SARCOMA.

XENETIC BIOSCIENCES, INC. ANNOUNCES ENTRY BY COLLABORATION PARTNER INTO A CLINICAL STUDY AGREEMENT TO ADVANCE DEVELOPMENT OF DNASE PLATFORM FOR THE TREATMENT OF RELAPSED/REFRACTORY OSTEOSARCOMA AND EWING SARCOMA

ENCOURAGING PRECLINICAL DATA SUPPORTING THE USE OF DNASE-BASED TECHNOLOGY TO TARGET NETOSIS AND ADDRESS DIFFICULT TO TREAT CANCERS STRATEGIC FOCUS ON EXPLORATORY INVESTIGATOR-INITIATED CLINICAL STUDIES WITH INSTITUTIONAL PARTNERS CONTINUED PROGRESS OF DNASE I DEVELOPMENT PROGRAM TOWARDS IND AND FIRST-IN-HUMAN STUDY FOR TREATMENT OF PANCREATIC CARCINOMA FRAMINGHAM, MA / ACCESS NEWSWIRE / MARCH 19, 2025 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNO-ONCOLOGY TECHNOLOGIES ADDRESSING DIFFICULT TO TREAT CANCERS, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024. RECENT HIGHLIGHTS EXTENDED ITS COLLABORATIONS WITH THE UNIVERSITY OF VIRGINIA AND SCRIPPS RESEARCH THROUGH 2025; ENTERED INTO A CLINICAL TRIAL SERVICES AGREEMENT WITH PERINESS LTD.

XENETIC BIOSCIENCES, INC. REPORTS FULL YEAR 2024 FINANCIAL RESULTS

DATA PRESENTED AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) SPRING SCIENTIFIC 2025 CELL THERAPY MEETING FINDINGS DEMONSTRATE THAT BY DEGRADING NEUTROPHIL EXTRACELLULAR TRAPS (NETS), DNASE I NOT ONLY FACILITATES INCREASED T CELL INFILTRATION BUT ALSO RESTORES T CELL FUNCTIONALITY, PAVING THE WAY FOR MORE EFFECTIVE CANCER TREATMENT STRATEGIES FRAMINGHAM, MA / ACCESS NEWSWIRE / MARCH 13, 2025 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNO-ONCOLOGY TECHNOLOGIES ADDRESSING DIFFICULT TO TREAT CANCERS, TODAY ANNOUNCED THE PRESENTATION OF PRECLINICAL DATA INVESTIGATING THE POTENTIAL OF CO-ADMINISTRATION OF DEOXYRIBONUCLEASE I (DNASE I) WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS IN A SYNGENEIC B16 MELANOMA MURINE MODEL OF LUNG METASTASIS. THE POSTER TITLED, " DNASE I INTERVENTION ENHANCES CAR-T CELL THERAPY IN SOLID TUMORS BY TARGETING NEUTROPHIL EXTRACELLULAR TRAPS IN METASTATIC MELANOMA ," WAS PRESENTED ON BEHALF OF THE COMPANY BY ALEXEY STEPANOV, PHD, INSTITUTE INVESTIGATOR AT THE SCRIPPS RESEARCH INSTITUTE, AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) SPRING SCIENTIFIC 2025 CELL THERAPY MEETING BEING HELD MARCH 12 - 14, 2025 IN SAN DIEGO, CA AND VIRTUALLY.

XENETIC BIOSCIENCES, INC. PRESENTS POSITIVE PRECLINICAL DATA UNDERSCORING THE POTENTIAL OF DNASE I AS AN ADJUNCTIVE TREATMENT TO ENHANCE IMMUNOTHERAPEUTIC RESPONSES

Xenetic Biosciences, Inc.

XBIO

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Xenetic Biosciences, Inc.

XBIO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

XBIO